Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

被引:9
|
作者
Giarola-Silva, Sarah [1 ]
Coelho-dos-Reis, Jordana G. A. [1 ]
Mourao, Marina Moraes [2 ]
Campi-Azevedo, Ana Carolina [1 ]
Nakagaki Silva, Erick E. [2 ]
Luiza-Silva, Maria [3 ]
Martins, Marina Angela [1 ]
de Oliveira Silveira-Cassette, Amanda Cardoso [1 ]
Batista, Mauricio Azevedo [1 ]
Peruhype-Magalhaes, Vanessa [1 ]
do Valle Antonelli, Lis Ribeiro [4 ]
Leite Ribeiro, Jose Geraldo [5 ]
Eloi-Santos, Silvana Maria [1 ,3 ]
Machado, Alexandre Vieira [6 ]
Teixeira-Carvalho, Andrea [1 ]
Martins-Filho, Olindo Assis [1 ]
Silva Araujo, Marcio Sobreira [1 ]
机构
[1] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
[4] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Biol & Imunol Parasitaria, Belo Horizonte, MG, Brazil
[5] Secretaria Estadual Saude Minas Gerais, Belo Horizonte, MG, Brazil
[6] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Imunol Doencas Virais, Belo Horizonte, MG, Brazil
关键词
H1N1; vaccine; AS03; adjuvant; Immune response; Biomarker signature; PANDEMIC H1N1 INFLUENZA; ADVERSE EVENTS; AS03; ADJUVANT; B-LYMPHOCYTES; CHILDREN; CYTOKINE; AGE; IMMUNOGENICITY; INTERLEUKIN-10; SIGNATURES;
D O I
10.1016/j.antiviral.2017.05.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4(+), CDS+ T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tIr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,1-6,1L-1 beta,1L-12,1-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4(+) and CD8(+) T-cells along with promiscuous production of IL-4/IL-5/1L-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8(+) T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4(+)/CD8(+) T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 82
页数:13
相关论文
共 50 条
  • [21] Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
    Andrews, Nick J.
    Walker, Woolf T.
    Finn, Adam
    Heath, Paul T.
    Collinson, Andrew C.
    Pollard, Andrew J.
    Snape, Matthew D.
    Faust, Saul N.
    Waight, Pauline A.
    Hoschler, Katja
    Sheasby, Liz
    Waddington, Claire
    Kerridge, Simon
    Chalk, Jeremy
    Reiner, Amanda
    John, Tessa
    Fletcher, Margaret
    Allen, Ruth
    Fineman, Natalie
    Wilkins, Su
    Casey, Michelle
    Michaelis, Louise
    Oeser, Clarissa
    Okike, Ifeanyichukwu
    Ladhani, Shamez
    Miller, Elizabeth
    VACCINE, 2011, 29 (45) : 7913 - 7919
  • [22] Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies
    Ide, Yuichiro
    Imamura, Yutaka
    Ohfuji, Satoko
    Fukushima, Wakaba
    Ide, Saburo
    Tsutsumi, Chiyo
    Koga, Masahisa
    Maeda, Kazuhiro
    Hirota, Yoshio
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) : 2387 - 2394
  • [23] Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis
    Sampaio-Barros, Percival D.
    Andrade, Danieli C. O.
    Seguro, Luciana C. P.
    Pasoto, Sandra G.
    Viana, Vilma S. T.
    Ribeiro, Ana C. M.
    Aikawa, Nadia E.
    Timenetsky, Maria do Carmo S.
    Precioso, Alexander R.
    Silva, Clovis A.
    Bonfa, Eloisa
    RHEUMATOLOGY, 2018, 57 (10) : 1721 - 1725
  • [24] Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
    Vaughn, David W.
    Seifert, Harry
    Hepburn, Anne
    Dewe, Walthere
    Li, Ping
    Drame, Mamadou
    Cohet, Catherine
    Innis, Bruce L.
    Fries, Louis F.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2942 - 2957
  • [25] A(H1N1) pdm09 influenza infection: vaccine inefficiency
    Friedman, Nehemya
    Drori, Yaron
    Pando, Rakefet
    Glatman-Freedman, Aharona
    Sefty, Hanna
    Bassal, Ravit
    Stein, Yaniv
    Shohat, Tamy
    Mendelson, Ella
    Hindiyeh, Musa
    Mandelboim, Michal
    ONCOTARGET, 2017, 8 (20) : 32856 - 32863
  • [26] Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
    Anders Madsen
    Åsne Jul-Larsen
    Mai-Chi Trieu
    Florian Krammer
    Rebecca J. Cox
    npj Vaccines, 6
  • [27] Enhanced Immune Response after a Second Dose of an AS03-Adjuvanted H1N1 Influenza A Vaccine in Patients after Hematopoietic Stem Cell Transplantation
    Gueller, Saskia
    Allwinn, Regina
    Mousset, Sabine
    Martin, Hans
    Wieters, Imke
    Herrmann, Eva
    Serve, Hubert
    Bickel, Markus
    Bug, Gesine
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (10) : 1546 - 1550
  • [28] Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
    Madsen, Anders
    Jul-Larsen, Asne
    Trieu, Mai-Chi
    Krammer, Florian
    Cox, Rebecca J.
    NPJ VACCINES, 2021, 6 (01)
  • [29] Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children
    Kotloff, Karen L.
    Halasa, Natasha B.
    Harrison, Christopher J.
    Englund, Janet A.
    Walter, Emmanuel B.
    King, James C.
    Creech, C. Buddy
    Healy, Sara A.
    Dolor, Rowena J.
    Stephens, Ina
    Edwards, Kathryn M.
    Noah, Diana L.
    Hill, Heather
    Wolff, Mark
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : 865 - 871
  • [30] Peripartum outcomes: non-adjuvanted v. adjuvanted H1N1 vaccination
    Ray, Joel G.
    McGeer, Allison J.
    Blake, Jennifer M.
    Lebovic, Gerald
    Smith, Graeme N.
    Yudin, Mark H.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (02) : 137 - 137